ARS Pharmaceuticals, Inc.

SPRYNASDAQHealthcare● Active

$9.26

+$0.27(+3.00%)

Market Cap$919548206

P/E Ratio—

52W High$18.9

52W Low$6.66

Avg Volume1.7M

Open$9.02

Beta0.83

Net Income Financials Revenue

ARS Pharmaceuticals, Inc. (SPRY) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

SPRY · net income · updated Jun 9, 2026

Core profitability metrics

SPRY · net income · margin · TTM · CAGR

Net income was −$171.3M for FY2025 (fiscal year ending 2025-12-31), down 2241.8% year-over-year. Net profit margin was -203.3%. Based on available data, ARS Pharmaceuticals, Inc. has been profitable since at least 2024.

FY2025 Net Income−$171.3M▼ -2241.8% YoY

Trailing 12M (TTM)−$198.0Mtrailing 4 quarters sum

Net Profit Margin-203.3%−$171.3M ÷ $84.3M

YoY Change-2241.8%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2024

▸ FMP /income-statement · Annual · SPRY net income history · SPRY profit margin

Annual net income data

SPRY · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$171.3M▼ 2241.8%-203.3%$84.3M

FY2024★ First Profit$8.0M▲ +114.7%9.0%$89.1M

FY2023Loss−$54.4M▼ 56.8%-181216.7%$30,000

FY2022Loss−$34.7M▼ 71.3%-2635.4%$1.3M

FY2021Loss−$20.2M▼ 1800.8%-367.6%$5.5M

Net income vs peers (Healthcare)

SPRY vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

ARS Pharmaceuticals, Inc.YOU

SPRY

−$171.3M-2241.8%-203.3%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

ARS Pharmaceuticals, Inc. (SPRY) reported net income of −$171.3M for FY2025 (fiscal year ending 2025-12-31), down 2241.8% year-over-year. The net profit margin was -203.3% — meaning the company kept $-2.03 of every dollar of revenue as profit.

Based on available data, ARS Pharmaceuticals, Inc. has been profitable since at least 2024. Net income reached a peak of $8.0M in FY2024. Data available for 8 fiscal years.

ARS Pharmaceuticals, Inc.'s net profit margin was -203.3% for FY2025, based on the latest annual results.

Investors sometimes search for "ARS Pharmaceuticals, Inc. net worth" — the company's market capitalization is a separate figure from SPRY net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

SPRY net income · 4 questions

ARS Pharmaceuticals, Inc. is not currently profitable on an annual basis. The company reported a net loss of $171.3M for FY2025.

is SPRY profitabledoes SPRY make a profitSPRY profitabilitySPRY profitable company

▸ Source: FMP /income-statement · GAAP · ARS Pharmaceuticals, Inc. · ARS Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026